Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.57
EXAC's Cash to Debt is ranked lower than
76% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. EXAC: 0.57 )
Ranked among companies with meaningful Cash to Debt only.
EXAC' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.19 Max: No Debt
Current: 0.57
Equity to Asset 0.81
EXAC's Equity to Asset is ranked higher than
79% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. EXAC: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
EXAC' s Equity to Asset Range Over the Past 10 Years
Min: 0.59  Med: 0.74 Max: 0.88
Current: 0.81
0.59
0.88
Interest Coverage 17.70
EXAC's Interest Coverage is ranked lower than
64% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 53.78 vs. EXAC: 17.70 )
Ranked among companies with meaningful Interest Coverage only.
EXAC' s Interest Coverage Range Over the Past 10 Years
Min: 6.39  Med: 16.85 Max: 28.71
Current: 17.7
6.39
28.71
F-Score: 5
Z-Score: 6.35
M-Score: -2.50
WACC vs ROIC
8.22%
6.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.17
EXAC's Operating margin (%) is ranked higher than
69% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. EXAC: 9.17 )
Ranked among companies with meaningful Operating margin (%) only.
EXAC' s Operating margin (%) Range Over the Past 10 Years
Min: 6.73  Med: 9.88 Max: 13.6
Current: 9.17
6.73
13.6
Net-margin (%) 6.13
EXAC's Net-margin (%) is ranked higher than
66% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.79 vs. EXAC: 6.13 )
Ranked among companies with meaningful Net-margin (%) only.
EXAC' s Net-margin (%) Range Over the Past 10 Years
Min: 4.3  Med: 6.30 Max: 7.57
Current: 6.13
4.3
7.57
ROE (%) 6.72
EXAC's ROE (%) is ranked higher than
64% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. EXAC: 6.72 )
Ranked among companies with meaningful ROE (%) only.
EXAC' s ROE (%) Range Over the Past 10 Years
Min: 5.87  Med: 7.99 Max: 10.86
Current: 6.72
5.87
10.86
ROA (%) 5.41
EXAC's ROA (%) is ranked higher than
69% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.56 vs. EXAC: 5.41 )
Ranked among companies with meaningful ROA (%) only.
EXAC' s ROA (%) Range Over the Past 10 Years
Min: 3.9  Med: 5.78 Max: 7.81
Current: 5.41
3.9
7.81
ROC (Joel Greenblatt) (%) 12.06
EXAC's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. EXAC: 12.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXAC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 9.09  Med: 13.13 Max: 18.6
Current: 12.06
9.09
18.6
Revenue Growth (3Y)(%) -1.10
EXAC's Revenue Growth (3Y)(%) is ranked lower than
65% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. EXAC: -1.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXAC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.1  Med: 14.20 Max: 30.5
Current: -1.1
-1.1
30.5
EBITDA Growth (3Y)(%) -2.00
EXAC's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. EXAC: -2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXAC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2  Med: 12.30 Max: 38
Current: -2
-2
38
EPS Growth (3Y)(%) 1.30
EXAC's EPS Growth (3Y)(%) is ranked lower than
51% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. EXAC: 1.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXAC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.5  Med: 13.50 Max: 34.6
Current: 1.3
-8.5
34.6
» EXAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

EXAC Guru Trades in Q1 2015

Jim Simons 46,900 sh (+6.11%)
Mario Gabelli 644,552 sh (+0.29%)
Chuck Royce 780,227 sh (-3.40%)
» More
Q2 2015

EXAC Guru Trades in Q2 2015

Jim Simons 53,700 sh (+14.50%)
Mario Gabelli 646,679 sh (+0.33%)
Chuck Royce 714,619 sh (-8.41%)
» More
Q3 2015

EXAC Guru Trades in Q3 2015

Jim Simons 66,500 sh (+23.84%)
Mario Gabelli 639,479 sh (-1.11%)
Chuck Royce 667,856 sh (-6.54%)
» More
Q4 2015

EXAC Guru Trades in Q4 2015

Jim Simons 79,400 sh (+19.40%)
Mario Gabelli 649,279 sh (+1.53%)
Chuck Royce 596,546 sh (-10.68%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Exactech Inc

Meridian Funds Comments on Exact Sciences Corp - Mar 08, 2016

Exact Sciences Corp. (NASDAQ:EXAC) declined after an independent panel of health care experts excluded the company’s colon cancer-screening test from a list of recommended tests in the U.S. Instead, the panel defined the product as “alternative testing that may be useful in select clinical circumstances.” Marketed as Cologuard, the product is a non-invasive, FDA-approved colorectal cancer-screening test covered by Medicare. It has proven effective at detecting early-stage colon cancer as well as precancerous lesions. When detected early, colon cancer is highly curable. However, Cologuard’s exclusion from the panel’s list of recommended tests may make it more difficult to win favorable reimbursement from private insurers. We consequently liquidated our position in Exact Sciences and used proceeds from the sale to invest in other, more attractive investment opportunities.





From the Meridian Equity Income Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 21.70
EXAC's P/E(ttm) is ranked higher than
60% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. EXAC: 21.70 )
Ranked among companies with meaningful P/E(ttm) only.
EXAC' s P/E(ttm) Range Over the Past 10 Years
Min: 13.61  Med: 21.41 Max: 34.81
Current: 21.7
13.61
34.81
Forward P/E 17.48
EXAC's Forward P/E is ranked higher than
65% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 18.69 vs. EXAC: 17.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.70
EXAC's PE(NRI) is ranked higher than
60% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 26.85 vs. EXAC: 21.70 )
Ranked among companies with meaningful PE(NRI) only.
EXAC' s PE(NRI) Range Over the Past 10 Years
Min: 13.63  Med: 21.41 Max: 35
Current: 21.7
13.63
35
Price/Owner Earnings (ttm) 45.54
EXAC's Price/Owner Earnings (ttm) is ranked lower than
68% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 30.19 vs. EXAC: 45.54 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EXAC' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.68  Med: 30.91 Max: 423.5
Current: 45.54
13.68
423.5
P/B 1.38
EXAC's P/B is ranked higher than
78% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. EXAC: 1.38 )
Ranked among companies with meaningful P/B only.
EXAC' s P/B Range Over the Past 10 Years
Min: 1.06  Med: 1.57 Max: 3.48
Current: 1.38
1.06
3.48
P/S 1.35
EXAC's P/S is ranked higher than
71% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. EXAC: 1.35 )
Ranked among companies with meaningful P/S only.
EXAC' s P/S Range Over the Past 10 Years
Min: 0.85  Med: 1.25 Max: 2.58
Current: 1.35
0.85
2.58
PFCF 37.78
EXAC's PFCF is ranked lower than
60% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 31.36 vs. EXAC: 37.78 )
Ranked among companies with meaningful PFCF only.
EXAC' s PFCF Range Over the Past 10 Years
Min: 14.43  Med: 33.21 Max: 2488
Current: 37.78
14.43
2488
POCF 11.61
EXAC's POCF is ranked higher than
79% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 19.89 vs. EXAC: 11.61 )
Ranked among companies with meaningful POCF only.
EXAC' s POCF Range Over the Past 10 Years
Min: 7.49  Med: 11.22 Max: 49.48
Current: 11.61
7.49
49.48
EV-to-EBIT 15.06
EXAC's EV-to-EBIT is ranked higher than
68% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 20.77 vs. EXAC: 15.06 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAC' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 14.35 Max: 21.6
Current: 15.06
9.2
21.6
EV-to-EBITDA 8.15
EXAC's EV-to-EBITDA is ranked higher than
82% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 16.43 vs. EXAC: 8.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 8.50 Max: 15
Current: 8.15
6
15
PEG 4.21
EXAC's PEG is ranked lower than
56% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. EXAC: 4.21 )
Ranked among companies with meaningful PEG only.
EXAC' s PEG Range Over the Past 10 Years
Min: 1.17  Med: 2.28 Max: 4.32
Current: 4.21
1.17
4.32
Shiller P/E 24.73
EXAC's Shiller P/E is ranked higher than
86% of the 42 Companies
in the Global Medical Devices industry.

( Industry Median: 39.60 vs. EXAC: 24.73 )
Ranked among companies with meaningful Shiller P/E only.
EXAC' s Shiller P/E Range Over the Past 10 Years
Min: 17.72  Med: 25.09 Max: 50.95
Current: 24.73
17.72
50.95
Current Ratio 5.69
EXAC's Current Ratio is ranked higher than
80% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. EXAC: 5.69 )
Ranked among companies with meaningful Current Ratio only.
EXAC' s Current Ratio Range Over the Past 10 Years
Min: 3.57  Med: 4.65 Max: 8.23
Current: 5.69
3.57
8.23
Quick Ratio 2.82
EXAC's Quick Ratio is ranked higher than
62% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. EXAC: 2.82 )
Ranked among companies with meaningful Quick Ratio only.
EXAC' s Quick Ratio Range Over the Past 10 Years
Min: 1.23  Med: 2.04 Max: 4.45
Current: 2.82
1.23
4.45
Days Inventory 348.35
EXAC's Days Inventory is ranked lower than
87% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 134.42 vs. EXAC: 348.35 )
Ranked among companies with meaningful Days Inventory only.
EXAC' s Days Inventory Range Over the Past 10 Years
Min: 330.22  Med: 349.35 Max: 363.57
Current: 348.35
330.22
363.57
Days Sales Outstanding 81.33
EXAC's Days Sales Outstanding is ranked lower than
59% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 70.19 vs. EXAC: 81.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.45  Med: 75.41 Max: 91
Current: 81.33
62.45
91
Days Payable 82.96
EXAC's Days Payable is ranked higher than
62% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 64.85 vs. EXAC: 82.96 )
Ranked among companies with meaningful Days Payable only.
EXAC' s Days Payable Range Over the Past 10 Years
Min: 52.26  Med: 75.56 Max: 90.48
Current: 82.96
52.26
90.48

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 3.82
EXAC's Price/Net Current Asset Value is ranked higher than
77% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. EXAC: 3.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EXAC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.87  Med: 4.43 Max: 18.45
Current: 3.82
1.87
18.45
Price/Tangible Book 1.62
EXAC's Price/Tangible Book is ranked higher than
82% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 3.66 vs. EXAC: 1.62 )
Ranked among companies with meaningful Price/Tangible Book only.
EXAC' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 2.20 Max: 3.73
Current: 1.62
1.26
3.73
Price/Projected FCF 1.77
EXAC's Price/Projected FCF is ranked higher than
58% of the 120 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. EXAC: 1.77 )
Ranked among companies with meaningful Price/Projected FCF only.
EXAC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.86  Med: 3.13 Max: 18.34
Current: 1.77
0.86
18.34
Price/DCF (Earnings Based) 1.87
EXAC's Price/DCF (Earnings Based) is ranked higher than
59% of the 17 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. EXAC: 1.87 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.08
EXAC's Price/Median PS Value is ranked lower than
52% of the 248 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. EXAC: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
EXAC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.79  Med: 1.23 Max: 2.15
Current: 1.08
0.79
2.15
Price/Peter Lynch Fair Value 3.51
EXAC's Price/Peter Lynch Fair Value is ranked lower than
72% of the 46 Companies
in the Global Medical Devices industry.

( Industry Median: 2.21 vs. EXAC: 3.51 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EXAC' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.94  Med: 1.91 Max: 4.11
Current: 3.51
0.94
4.11
Price/Graham Number 1.25
EXAC's Price/Graham Number is ranked higher than
70% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. EXAC: 1.25 )
Ranked among companies with meaningful Price/Graham Number only.
EXAC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.95  Med: 1.48 Max: 2.19
Current: 1.25
0.95
2.19
Earnings Yield (Greenblatt) (%) 6.61
EXAC's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. EXAC: 6.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXAC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.6  Med: 7.00 Max: 10.8
Current: 6.61
4.6
10.8
Forward Rate of Return (Yacktman) (%) 7.23
EXAC's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. EXAC: 7.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EXAC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.8  Med: 9.90 Max: 14
Current: 7.23
3.8
14

More Statistics

Revenue(Mil) $246
EPS $ 1.06
Beta0.88
Short Percentage of Float4.32%
52-Week Range $16.11 - 24.69
Shares Outstanding(Mil)14.03

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 252 261 270
EPS($) 1.15 1.25 1.25
EPS without NRI($) 1.15 1.25 1.25

Business Description

Industry: Medical Devices » Medical Devices
Compare:HKSE:00853, TSE:6960, NAS:SPNC, LSE:CSRT, HKSE:01302, NAS:KTWO » details
Exactech Inc was founded by an orthopaedic surgeon in November 1985, and is incorporated under the laws of the State of Florida. The Company develops, manufactures, markets, distributes and sella orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Its U.S. sales and distribution activities are conducted by its wholly owned subsidiary Exactech U.S., Inc. The Companys international development, sales and distribution activities are conducted by its wholly owned subsidiary Exactech International Operations, AG based in Bern, Switzerland. The Company manufactures some components of its knee, extremity, and hip joint replacement systems at its facility in Gainesville, Florida, utilizing modern, highly automated computer aided manufacturing equipment. Its cellular based manufacturing processes, which are organized in groups, or cells, are dedicated to specific product lines to minimize change-over and increase efficiency. To supplement its manufacturing of components, the company has formed strategic alliances with suppliers and business partners to externally manufacture some components. Additionally, the company acquires and distribute other products and services through exclusive agreements, such as its agreement with Tecres S.p.A, (Tecres) and Blue Ortho, SAS (Blue Ortho), and non-exclusive agreements, such as with RTI Surgical, Inc., (RTI), and Biomatlante SARL, (Biomatlante). The company markets its orthopaedic implant products in the United States through Exactech U.S., Inc. that operates through a network of independent sales agencies and direct sales representatives. The company offers its products in all fifty states, Puerto Rico, and the District of Columbia. The Companys competitors in the orthopaedic market are DePuy, Inc., a division of Johnson and Johnson, Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., Stryker Corporation, Smith and Nephew plc, and Biomet, Inc. The Companys operations are subject to numerous and increasingly stringent federal, state and local environmental laws and regulations in the United States and other countries in which they operates.
» More Articles for EXAC

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Exact Sciences Corp Mar 08 2016 
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 28 2013 
Mario Gabelli Ups His Holdings in EXAC, TWIN and LAYN Jun 28 2013 
Exactech Inc. Reports Operating Results (10-K) Mar 16 2011 
Exactech Inc. Reports Operating Results (10-Q) Nov 09 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Exactech Inc. Reports Operating Results (10-Q) May 05 2010 
Exactech Inc. (EXAC) CFO and Treasurer Joel C Phillips sells 2,497 Shares May 04 2010 
Exactech Inc. (EXAC) CEO and Chairman, 10% Owner R William Petty sells 20,000 Shares Dec 11 2009 
Exactech Inc. Reports Operating Results (10-Q) Nov 05 2009 

More From Other Websites
Exactech Inc. (Nasdaq: EXAC) to Ring The Nasdaq Stock Market Closing Bell May 02 2016
Exactech Inc. (Nasdaq: EXAC) to Ring The Nasdaq Stock Market Closing Bell May 02 2016
Exactech Celebrates 20-Year Nasdaq Listing Anniversary May 02 2016
EXACTECH INC Files SEC form 10-Q, Quarterly Report Apr 29 2016
Exactech, Inc. :EXAC-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 28 2016
Edited Transcript of EXAC earnings conference call or presentation 27-Apr-16 2:00pm GMT Apr 27 2016
Exactech posts 1Q profit Apr 26 2016
Exactech posts 1Q profit Apr 26 2016
EXACTECH INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Apr 26 2016
Exactech Q1 Revenue Up 6% to $65.3 Million Apr 26 2016
Q1 2016 Exactech Inc Earnings Release - After Market Close Apr 26 2016
Exactech Receives FDA 510(k) Clearance for Vantage™ Total Ankle Apr 25 2016
Exactech upgraded by Robert W. Baird Apr 13 2016
Exactech Schedules First Quarter 2016 Earnings Release and Conference Call Apr 12 2016
Statement - Full Year 2015 results Apr 05 2016
Strength Seen in Exactech (EXAC): Stock Rises 5.6% Apr 01 2016
Exactech Announces Completion of Corporate Integrity Agreement Requirements Mar 10 2016
EXACTECH INC Financials Mar 09 2016
EXACTECH INC Files SEC form 10-K, Annual Report Mar 03 2016
Exactech Innovations Presented at 2016 Orthopaedic Research Society Annual Meeting Mar 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK